or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

R^1 is
1) -CN,
2) $-NO_2$,
3) a halogen, or
4) $(C_1\text{-}C_4)$-alkyl-C(O)-OH;

R^2 is
1) $-CF_3$,
2) a halogen, or
3) -CN;

R^3 is
1) =O,
2) =S, or
3) =NH;

X is
1) a radical of formula II



(II)

or

2) a radical of formula III



(III)

or X and Y together form a group of formula IV



(IV)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

in which R^4 is 1) hydrogen atom,

2) $(C_1\text{-}C_6)$-alkyl-,

3) $(C_2\text{-}C_6)$-alkenyl-, or

4) $(C_1\text{-}C_6)$-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,

4.2 halogens,

4.3 -O-$(C_1\text{-}C_4)$-alkyl,

4.4 -CN, or

4.5 -SH;

Y is 1) a radical of formula V



(V)

in which:

R^5 is, independently of R^6, a hydrogen atom or $(C_1\text{-}C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5, $(C_1\text{-}C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

a) halogens,

b) phenyl-$(CH_2)_m$-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

-COOH, - CN, or -CF_3, and m is the integer zero, 1, 2, 3, 4, 5, or 6,

c) -COOH,

d) -CN, or

e) -CF_3, or

2) a radical of formula VI,



(VI)

in which R^4 is as defined above; and

Z is 1) -O- or

2) a radical of formula VII



(VII).

wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

22. (Amended) A process for making a product for treatment of androgenic alopecia, comprising the step of forming said product by bringing together:

a) at least one physiologically tolerated film-forming agent;

b) at least one physiologically tolerated solvent;

c) at least one plasticizer; and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

d) a compound of the formula I



(I)

B2 Cont

or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

R^1 is
1) -CN,
2) $-NO_2$,
3) a halogen, or
4) $(C_1\text{-}C_4)$-alkyl-C(O)-OH;

R^2 is
1) $-CF_3$,
2) a halogen, or
3) -CN;

R^3 is
1) =O,
2) =S, or
3) =NH;

X is
1) a radical of formula II



(II)

or

2) a radical of formula III

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



(III)

or X and Y together form a group of formula IV



(IV)

in which R^4 is 1) hydrogen atom,

2) $(C_1\text{-}C_6)$-alkyl-,

3) $(C_2\text{-}C_6)$-alkenyl-, or

4) $(C_1\text{-}C_6)$-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,

4.2 halogens,

4.3 -O-$(C_1\text{-}C_4)$-alkyl,

4.4 -CN, or

4.5 -SH;

Y is 1) a radical of formula V



(V)

in which:

R^5 is, independently of R^6, a hydrogen atom or $(C_1\text{-}C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5, $(C_1\text{-}C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

B2 Cont

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

a) halogens,

b) phenyl-$(CH_2)_m$-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, - CN, or $-CF_3$, and m is the integer zero, 1, 2, 3, 4, 5, or 6,

c) -COOH,

d) -CN, or

e) $-CF_3$, or

2) a radical of formula VI,



(VI)

in which R^4 is as defined above; and

Z is 1) -O- or

2) a radical of formula VII



(VII),

wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

23. (Amended) A process for making a product intended for treatment of seborrhea or acne, comprising the step of forming said product by bringing together:

a) at least one physiologically tolerated film-forming agent;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

b) at least one physiologically tolerated solvent;

c) at least one plasticizer; and

d) a compound of the formula I



(I)

or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

R^1 is 1) -CN,

2) $-NO_2$,

3) a halogen, or

4) $(C_1\text{-}C_4)$-alkyl-C(O)-OH;

R^2 is 1) $-CF_3$,

2) a halogen, or

3) -CN;

R^3 is 1) =O,

2) =S, or

3) =NH;

X is 1) a radical of formula II



(II)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B2 Cont

or

2) a radical of formula III



(III)

or X and Y together form a group of formula IV



(IV)

in which R^4 is 1) hydrogen atom,

2) $(C_1\text{-}C_6)$-alkyl-,

3) $(C_2\text{-}C_6)$-alkenyl-, or

4) $(C_1\text{-}C_6)$-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,

4.2 halogens,

4.3 -O-$(C_1\text{-}C_4)$-alkyl,

4.4 -CN, or

4.5 -SH;

Y is 1) a radical of formula V



(V)

in which:

R^5 is, independently of R^6, a hydrogen atom or $(C_1\text{-}C_4)$-alkyl,

wherein the alkyl is unsubstituted or mono- to tetrasubstituted by

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

halogens, and R^6 is, independently of R^5, $(C_1$-$C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

a) halogens,

b) phenyl-$(CH_2)_m$-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, - CN, or $-CF_3$, and m is the integer zero, 1, 2, 3, 4, 5, or 6,

c) -COOH,

d) -CN, or

e) $-CF_3$, or

2) a radical of formula VI,



(VI)

in which R^4 is as defined above; and

Z is 1) -O- or

2) a radical of formula VII



(VII).

wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B3 Subt C1

28. (Amended) A process for treatment of seborrhea or acne, comprising the step of applying to a patient in need or desire thereof a composition comprising:

a) at least one physiologically tolerated film-forming agent;

b) at least one physiologically tolerated solvent;

c) at least one plasticizer; and

d) a compound of the formula I



(I)

or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

R^1 is 1) -CN,

2) $-NO_2$,

3) a halogen, or

4) $(C_1\text{-}C_4)$-alkyl-C(O)-OH;

R^2 is 1) $-CF_3$,

2) a halogen, or

3) -CN;

R^3 is 1) =O,

2) =S, or

3) =NH;

X is 1) a radical of formula II

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B3 Cont



(II)

or

2) a radical of formula III



(III)

or X and Y together form a group of formula IV



(IV)

in which R^4 is 1) hydrogen atom,

2) $(C_1\text{-}C_6)$-alkyl-,

3) $(C_2\text{-}C_6)$-alkenyl-, or

4) $(C_1\text{-}C_6)$-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,

4.2 halogens,

4.3 -O-$(C_1\text{-}C_4)$-alkyl,

4.4 -CN, or

4.5 -SH;

Y is 1) a radical of formula V



(V)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B3 cont

in which:

R^5 is, independently of R^6, a hydrogen atom or $(C_1$-$C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5, $(C_1$-$C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

a) halogens,

b) phenyl-$(CH_2)_m$-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or $-CF_3$, and m is the integer zero, 1, 2, 3, 4, 5, or 6,

c) -COOH,

d) -CN, or

e) $-CF_3$, or

2) a radical of formula VI,



(VI)

in which R^4 is as defined above; and

Z is 1) -O- or

2) a radical of formula VII



(VII).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

B3 cont

29. (Amended) A cosmetic composition comprising:

a) at least one physiologically tolerated film-forming agent;

b) at least one physiologically tolerated solvent;

c) at least one plasticizer; and

d) a compound of the formula I



(I)

or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

R^1 is
1) -CN,
2) $-NO_2$,
3) a halogen, or
4) $(C_1\text{-}C_4)$-alkyl-C(O)-OH;

R^2 is
1) $-CF_3$,
2) a halogen, or
3) -CN;

R^3 is
1) =O,
2) =S, or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

3) =NH;

X is 1) a radical of formula II



(II)

or

2) a radical of formula III



(III)

or X and Y together form a group of formula IV



(IV)

in which R^4 is 1) hydrogen atom,

2) $(C_1\text{-}C_6)$-alkyl-,

3) $(C_2\text{-}C_6)$-alkenyl-, or

4) $(C_1\text{-}C_6)$-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,

4.2 halogens,

4.3 -O-$(C_1\text{-}C_4)$-alkyl,

4.4 -CN, or

4.5 -SH;

Y is 1) a radical of formula V



(V)

-15-

B3 Cont

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B3 Cont

in which:

R^5 is, independently of R^6, a hydrogen atom or $(C_1$-$C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5, $(C_1$-$C_4)$-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

a) halogens,

b) phenyl-$(CH_2)_m$-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, - CN, or $-CF_3$, and m is the integer zero, 1, 2, 3, 4, 5, or 6,

c) -COOH,

d) -CN, or

e) $-CF_3$, or

2) a radical of formula VI,

(VI)

in which R^4 is as defined above; and

Z is 1) -O- or

2) a radical of formula VII



(VII).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com